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Abstract
The present study was performed to elucidate the hypocholesterolemic action of chitosan on the diet-induced hypercholesterolemia in rats. Male
Sprague-Dawley rats (n=24) were fed with chitosan-free diet (Control), diets containing 2% or 5% chitosan for 4 weeks. Hypercholesterolemia was
induced by adding 1% cholesterol and 0.5% cholic acid to all diets. Body weight gain and food intake of rats did not differ among the groups.
The chitosan treated groups showed significant improvement in the plasma concentration of total cholesterol and LDL-cholesterol compared to the
control group (p<0.05). Also, the chitosan treated groups decreased the liver concentration of total lipid and total cholesterol compared to the control
group (p<0.05). The activity of hepatic cholesterol 7α-hydroxylase (CYP7A1), the rate-limiting enzyme in the conversion of cholesterol to bile acids,
was increased by 123% and 165% for the 2% or 5% chitosan diets, respectively. These findings suggest that enhancement of hepatic CYP7A1
activity may be a mechanism, which can partially account for the hypocholesterolemic effect of dietary chitosan in cholesterol metabolism.
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Introduction2)
An increased blood cholesterol level is one of the major risk 
factors for the development of coronary heart disease (CHD) 
(Assmann  et al., 1999). Risk factors for CHD include aging, 
hypercholesterolemia, hypertension and hyperlipidemia (Castelli 
et al., 1986). A high blood cholesterol level is ranked as one 
of the greatest risk factors contributing to the prevalence and 
severity of CHD (Grundy, 1986; Neaton et al., 1984). The blood 
cholesterol level is determined by the balance among the dietary 
cholesterol, cholesterol biosynthesis and conversion of chole-
sterol to bile acids in the liver, and cholesterol absorption and 
reuptake by the small intestine (Assmann et al., 1999). Chole-
sterol 7α-hydroxylase (CYP7A1) is a liver-specific cytochrome 
P450 isozyme of the CYP7A family that catalyzes the rate- 
limiting step in the classic pathway of bile acid biosynthesis. 
Conversion of cholesterol to bile acids in the liver is the most 
important pathway for the elimination of cholesterol from the 
body (Turley & Dietschy, 1988). Transcription of CYP7A1 is 
inhibited in a feedback mechanism by bile acids and stimulated 
in a feed-forward mechanism by cholesterol (Guorong et al., 
2004; Spady et al., 1996).
Chitosan is obtained by the deacetylation of chitin, an ami-
nopolysaccharide found in the exoskeletons and the fungal cell 
wall of various arthropods including insects, crabs and shrimps 
(Muzzarelli, 1977). Although it is not derived from plants, it 
shares the same characteristics as dietary fiber, which is a 
polysaccharide indigestible by mammalian digestive enzymes. 
When ingested, chitosan develops an HCl-layer in the stomach. 
As capsulated particles of chitosan move into the duodenum, the 
HCl-layer becomes diluted and the chitosan particles form 
agglomerates with fatty acids and cholesterol, thus reducing lipid 
absorption from the gastrointestinal tract. Studies in primates 
have shown that chitosan can increase the amount of fat 
eliminated in the stool (Ebihara et al., 1989; Sugano et al., 1980).
Several studies showed that chitosan had a potent plasma lipid 
lowering effect in the rat (Hossain et al., 2007; Sugano et al., 
1980; Xu et al., 2007) and human (Bokura & Kobayashi, 2003; 
Gallaher et al., 2002; Guha et al., 2005). Daily fecal bile acid 
excretion in the 7.5% chitosan group was more than twofold 
greater than that of the control and glucomannan groups (Gallaher 
et al., 2000). Maezaki et al. (1993) reported increased fecal 
excretion of two bile acids, cholic and chenodeoxycholic acid 
in male subjects consuming 3 to 6 g/day of chitosan. In rats, 
chitosan increased (Sugano et al., 1980) or had no effect (Fukada 
et al., 1991) in fecal neutral sterol excretion. The 3-hydroxy-3- 
methyl glutaryl-CoA (HMG-CoA) reductase activity was ele-
vated in chitosan group although it was lower than that of the 
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Table 1. Compositions of experimental diets
1)
Control 2% chitosan 5% chitosan
(g/100 g diet)
Casein 20 20 20
D,L-methionine 0.3 0.3 0.3
Corn starch 15 15 15
Sucrose 48.5 48.5 48.5
Cellulose 5 3 0
Corn oil 5 5 5
Mineral mix(AIN-76)
2) 3.5 3.5 3.5
Vitamin mix(AIN-76)
3) 11 1
Choline bitartarate 0.2 0.2 0.2
Cholesterol 1 1 1
Cholic acid 0.5 0.5 0.5
Chitosan 0 2 5
Total 100 100 100
1) Diets were AIN-76 semipurified, and given in powdered form.
2) AIN-76 mineral mixture. 
3) AIN-76 vitamin mixture.
cholesterol free group, whereas the HMG-CoA reductase mRNA 
levels were not changed (LeHoux & Grondin, 1993). 
Investigations of the hypocholesterolemic effect of chitosan 
have focused on greater excretion of bile acids and total steroids 
leading to the increase of bile acid biosynthesis. Synthesis of 
bile acids from cholesterol is regulated by feedback inhibition 
of the rate-limiting enzyme, cholesterol 7α-hydroxylase (CYP-
7A1) (Danielsson et al., 1975). However, the effect of chitosan 
on the activity of liver CYP7A1 has not been described. 
Therefore, the purpose of this study was to investigate the 
effects of chitosan on plasma and liver cholesterol levels in 
cholesterol-fed rats. Additionally, we determined whether chito-




Three groups of male Sprague-Dawley rats (initial weights, 130
± 5 g, SLC, Japan) were housed individually in a light controlled 
room (dark, 06:00-18:00 hour) at a temperature of 22 ± 2℃ and 
relative humidity 55 ± 5%. Rats were given free access to a 
non-purified diet (Ralston Purina, St Louis, MO) and tap water 
for 1 week to be acclimatized before the experiment. Rats were 
randomly divided into three groups and assigned to different 
dietary treatments. The compositions of the experimental diets 
are shown in Table 1. Experimental diets employed were 
modifications of the AIN-76 purified rodent diet (Dyets, 
Bethlehem, PA). Rats were fed chitosan-free diets (control), diets 
with the addition of 2% or 5% chitosan and tap water ad libitum 
for 4 weeks. Chitosan from sea crab shell was obtained from 
Iljin Pharm Co. Ltd., Korea. All diets contained 1% cholesterol 
and 0.5% cholic acid in order to induce hypercholesterolemia. 
The Rats were given free access to food and water for 4 weeks, 
and food intake and body weight gain were monitored twice a 
week. At the end of the experiment, rats were anesthetized and 
a central longitudinal incision was made into the abdominal wall, 
and blood samples were collected by cardiac puncture. Blood 
samples were centrifuged at 1,500 × g for 20 minutes at 4℃ and 
the plasma was separated and stored at -20℃ until analyzed. 
Liver samples were excised, immediately frozen in liquid 
nitrogen and stored at -70℃. All animal procedures conformed 
to NIH guidelines as stated in the “Principles of Laboratory 
Animal Care” published by the National Institutes of Health 
(publication No. 86-23, revised 1985).
Lipids analysis
The plasma total cholesterol, HDL-cholesterol and triglyceride 
levels were determined by enzymatic colorimetric methods using 
commercial kits (Asan Pharmaceutical, Seoul, Korea). Plasma 
LDL-cholesterol was calculated by the formula of Friedewald 
et al. (1972). Total lipids in the liver were extracted with a 
chloroform: methanol mixture (2：1, v/v) as described by Folch 
et al.(1956). The concentration of liver cholesterol in the lipid 
extracts was measured enzymatically by using a kit (Asan 
Pharmaceutical, Seoul, Korea).
Assay of microsomal cholesterol 7α-hydroxylase activity
CYP7A1 activity was assayed using the procedure of Oda et 
al. (1989). About 2 g of liver was homogenized in 4 volumes 
of 0.1 M potassium phosphate buffer (pH 7.4) containing 1 mM 
EDTA and 50 mM NaF. The homogenates were centrifuged at 
12,000 × g for 15 minutes, and the supernatant was re-centrifuged 
at 100,000 × g for 60 minutes. The microsomal pellet was 
suspended in 2 ml of 0.1 M potassium phosphate buffer (pH 
7.4) containing 0.1 mM EDTA, 50 mM NaF, 2 mM NADPH, 
20 mM cysteamine, 200 µM cholesterol, 1.5 g Tween 80, and 
6 µCi [7(n)-
3H] cholesterol (Amersham, UK). Incubation was 
carried out at 37℃ for 30 minutes. The reaction was stopped 
by the addition of 6 ml of 20% trichloroacetic acid. Subsequently, 
the reaction mixture was centrifuged at 1,500 × g for 10 minutes. 
Chloroform was added to the supernatant to extract the radio-
labeled cholesterol. After the second extraction with chloroform, 
1 ml of the upper aqueous phase was transferred, and the 
radioactivity was quantified with a liquid scintillation counter. 
The protein content in microsomes was measured according to 
Bradford (1976).
Statistical analysis
Data are expressed as mean ± SD. The significant differences 
among groups were determined by one-way analysis of variance 
using the SPSS package program, version 11.0 (SPSS, Chicago, 
IL, USA). The results were considered significant if the value Min-Sun Moon et al. 177
Table 2. Body weight gain, food intake, FER and lipid profiles of rats
1,2)
Control 2% chitosan 5% chitosan
Body weight gain (g/d)   5.64 ± 0.55
NS3) 5.35 ± 0.34 4.97 ± 0.41
Food intake (g/d) 25.39 ± 2.41
NS 22.49 ± 1.83 23.41 ± 1.20
FER
4) (g/d)  0.25 ± 0.02
NS 0.26 ± 0.02 0.22 ± 0.03
Serum lipids (mg/dl)
Total cholesterol  190.59 ± 31.59
a 157.40 ± 36.67
b 133.63 ± 15.29
b
LDL-cholesterol
5) 126.74 ± 16.25
a  91.28 ± 19.80
b 74.72 ± 2.21
b
HDL-Cholesterol 41.60 ± 8.09
NS 40.71 ± 9.75 34.95 ± 11.06
Triglyceride 111.23 ± 36.29
NS 127.04 ± 35.62 119.82 ± 32.20
AI
6)  3.58 ± 1.84
NS 2.87 ± 0.67 2.82 ± 0.27
Liver lipids (mg/g liver)
Total lipid 40.14 ± 23.82
a 32.05 ± 6.75
ab 17.89 ± 7.07
b
Total cholesterol 10.97 ± 3.49
a 10.23 ± 2.08
a 6.41 ± 1.42
b
1)  Values  are  expressed  as  mean ± SD  (n=8). 
2) Values in a column with different superscripts are significantly different, p＜0.05. 
3) N S  i s  n o t  s i g n i f i c a n t .
4)  Food  efficiency  ratio  (FER)=body  weight  gain  (g/d)/food  intake ( g / d ) . 
5)  LDL  cholesterol  was  calculated  by  the  method  of  Friedewald  WT  formula. 
6)  AI  (Atherogenic  Index)=(Total  Cholesterol-HDL-Cholesterol)/HDL-Cholesterol.
Fig. 1. Effect of dietary chitosan on hepatic CYP7A1 activity in cholesterol-fed 
rats.  Values  are  expressed  as  mean ± SD,  n = 8.  Different  superscripts  are 
significantly  different  (p＜0.05).
of p was <0.05, and Duncan’s multiple range test was performed 
if differences were identified between groups.
Results
Body weight gain, food intake, FER and lipid profiles
Body weight gain, food intake and food efficiency ratio (FER) 
of rats did not differ among the groups, in spite of chitosan 
supplementation (Table 2). Rats treated with 2% or 5% chitosan 
had significantly lower plasma total cholesterol concentrations 
by 17% and 30%, respectively, than that of rats fed the control 
diet. Also, the 2% or 5% chitosan groups significantly decreased 
plasma LDL-cholesterol concentrations by 28% and 41%, 
respectively, while the plasma HDL-cholesterol and triglyceride 
concentrations were not significantly affected. The atherogenic 
index (AI) was decreased by chitosan supplementation. In 
addition, total lipid and total cholesterol in liver were signi-
ficantly decreased by 57% and 40%, respectively, in 5% chitosan 
diet compared to the control group (Table 2). 
Hepatic CYP7A1 activity 
Consumption of chitosan diet resulted in the elevated activity 
of hepatic CYP7A1 compared to the control group. The 2% or 
5% chitosan diet increased the activity of CYP7A1 by 123% 
and 165%, respectively, compared to the control group (Fig. 1).
Discussion
Our study was carried out in order to clarify how chitosan 
affects the cholesterol metabolism in hypercholesterolemic rats. 
The results showed that concentrations of plasma cholesterol in 
rats fed chitosan were reduced. In this study, we added 2% or 
5% chitosan to diet containing 1% cholesterol and 0.5% cholic 
acid and treated rats for 4 weeks. Consumption of 2% or 5% 
chitosan did not suppress body weight gain, food intake and food 
efficiency compared to the control group. Similar to our results, 
Sugano et al. (1980) reported that intake of 2% or 5% chitosan 
was not significantly different in body weight gain and food 
intake.
After 4 weeks of experimental period, chitosan diets showed 
positive results showing reduction in the plasma total cholesterol, 
LDL-cholesterol and atherogenic index in diet-induced hyper-
cholesterolemic rats. The hypocholesterolemic effects of chitosan 
diets tested were as follows: chitosan 5% > chitosan 2% > 
control. Razdan et al. (1994) showed that feeding of chitosan- 
containing diets generally reduced the plasma total cholesterol 
and HDL cholesterol concentrations and gave an increased HDL 
to total cholesterol ratio in comparison with chickens given the 
control and chitin-containing diet. However, no significant 
reductions in the plasma triacylglyceride concentrations resulted 
from feeding of the chitosan-containing diets were observed.
To evaluate effects of dietary fiber on the cholesterol meta-
bolism, the dietary cholesterol concentrations usually employed 
were ranged from 0.2% to 1%. Our diet included 1% cholesterol 
and 0.5% cholic acid. The ability of chitosan to improve 
cholesterol metabolism might have several explanations. Addi-
tion of 2, 5 or 10% chitosan resulted in a significant reduction 
in the plasma cholesterol, liver cholesterol and triacylglyceride 
but 10% level of chitosan depressed the animal growth (Sugano 
et al., 1980). These results implied that high dose (more than 
10%) of chitosan might be toxic to the rat. The most commonly 
reported adverse effects of chitosan are gastrointestinal problems, 
such as nausea, diarrhea and constipation. These effects generally 
do not cause discontinuation of chitosan use (Hendler et al., 
2001). 
Chitosan treatment decreased the liver total lipid and total 178 Hypocholesterolemic effect of dietary chitosan
cholesterol contents compared to the control diet. Similar to our 
results, Chiang et al. (2000) reported that intake of 5% high 
viscosity chitosan and 5% low viscosity chitosan decreased the 
liver total lipids and total cholesterol concentrations compared 
to the control group. 
Chitosan has been shown to be hypocholesterolemic based on 
the mechanism of greater excretion of bile acids and total steroids 
leading to an up-regulation of bile acid biosynthesis (Fukada et 
al., 1991; Gallaher et al., 2000; Maezaki et al., 1993; Murata 
et al., 2006). However, the effects of chitosan on the bile acid 
synthesizing enzyme, CYP7A1, have not been investigated. 
In our results, supplementation of chitosan increased the 
activity of hepatic microsomal CYP7A1. A plausible mechanism 
for the hypocholesterolemic activity of chitosan is its up- 
regulation of fecal neutral acids excretion. Conversion of 
cholesterol to neutral acids is the major pathway of cholesterol 
elimination (Kelly, 2003). The chitosan in the diet may lead to 
a diminished absorption of bile acids, thereby resulting in 
up-regulation of hepatic CYP7A1 activity. By feeding chitosan 
to rats, the CYP7A1 activity was stimulated compared to the 
control, resulting in the hypocholesterolemic effect. Our finding 
indicated that chitosan may possess hypocholesterolemic actions, 
which operate in a manner dependent of CYP7A1 activity.
In conclusion, the addition of chitosan to rats had a beneficial 
effect on the cholesterol metabolism. Chitosan treatment 
enhanced the hepatic CYP7A1 activity, which was associated 
with the decrease in the plasma total cholesterol level. Increase 
in the CYP7A1 activity may play a role in the hypochole-
sterolemic action of chitosan in vivo. Thus, the consumption of 
chitosan may be considerably beneficial to hypercholesterolemic 
patients. Further research is required to fully delineate the 
mechanisms that contribute to the hypocholesterolemic effects 
of chitosan and its constituents.
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